Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: Results from the phase II GAUGUIN study

Journal of Clinical Oncology

Volumn 31, Issue 23, 2013, Pages 2912-2919

  Morschhauser, Franck Andre ^a   Cartron, Guillaume ^b   Thieblemont, Catherine ^c   Solal Céligny, Philippe ^d   Haioun, Corinne ^e   Bouabdallah, Reda ^f   Feugier, Pierre ^g   Bouabdallah, Krimo ^h   Asikanius, Elina ^j   Lei, Guiyuan ^k   Wenger, Michael ^j   Wassner Fritsch, Elisabeth ^j   Salles, Gilles Andre ⁱ  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d Cancérologie de l'Ouest Institute   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f INSTITUT PAOLI CALMETTES   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h BORDEAUX UNIVERSITY HOSPITAL   (France)

ⁱ HOSPICES CIVILS DE LYON   (France)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

^k NONE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHISTAMINIC AGENT; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; CREATININE; FC RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; OBINUTUZUMAB; PARACETAMOL; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIFFUSE LARGE B CELL LYMPHOMA; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART FAILURE; HUMAN; HUMORAL IMMUNE DEFICIENCY; INFUSION RELATED REACTION; LIMB PAIN; LYMPHOCYTOPENIA; MALE; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; CLINICAL TRIAL; DRUG ADMINISTRATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; METABOLISM; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED;

EID: 84891442057     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.9585     Document Type: Article

References (33)

1. Sehn LH, Donaldson J, Chhanabhai M, et al: Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027-5033, 2005.
2. Gisselbrecht C, Glass B, Mounier N, et al: R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol 27:436s, 2009 (suppl; abstrt 8509).
3. Glass B, Borgerding A, Ziepert M, et al: Outcome of elderly patients with DLBCL failing RCHOP: The role of rituximab and high dose therapy in second line treatment-A retrospective analysis from the RICOVER 60 trial. Blood 114, 2009 (abstr 3714).
4. Martín A, Conde E, Arnan M, et al: R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: The influence of prior exposure to rituximab on outcome-A GEL/TAMO study. Haematologica 93:1829-1836, 2008.
5. El Gnaoui T, Dupuis J, Belhadj K, et al: Rituximab, gemcitabine and oxaliplatin: An effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 18:1363-1368, 2007.
6. Gisselbrecht C, Glass B, Mounier N, et al: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184-4190, 2010.
7. Kluin-Nelemans HC, Hoster E, Hermine O, et al: Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367:520-531, 2012.
8. Glennie MJ, French RR, Cragg MS, et al: Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44:3823-3837, 2007.
9. Morschhauser F, Leonard JP, Fayad L, et al: Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: Phase I/II results. J Clin Oncol 27:3346-3353, 2009.
10. Morschhauser F, Marlton P, Vitolo U, et al: Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 21:1870-1876, 2010.
11. Chan HT, Hughes D, French RR, et al: CD20- induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 63:5480- 5489, 2003.
12. Cragg MS, Glennie MJ: Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103:2738-2743, 2004.
13. Alduaij W, Ivanov A, Honeychurch J, et al: Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actindependent, lysosome-mediated cell death in B-cell malignancies. Blood 117:4519-4529, 2011.
14. Honeychurch J, Alduaij W, Azizyan M, et al: Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood 119:3523-3533, 2012.
15. Mossner E, Brünker P, Moser S, et al: Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115:4393-4402, 2010.
16. Sehn LH, Assouline SE, Stewart DA, et al: A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 119:5118- 5125, 2012.
17. Salles G, Morschhauser F, Lamy T, et al: Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) (GA101) in B-cell lymphoma patients. Blood 119:5126-5132, 2012.
18. Meneses-Lorente G, Carlile D, Birkett J, et al: Pharmacokinetics of RO5072759 (GA101) in patients with relapsed/refractory CD20- malignant disease (phase I/II study BO20999). Blood 116, 2010 (abstr 1833).
19. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999.
20. Pfreundschuh M, Held G, Zeynalova S, et al: Improved outcome of elderly poor-prognosis DLBCL patients with 6 x CHOP-14 and 8 applications of rituximab (R) given over an extended period: Results of the SMARTE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Blood 118, 2011 (abstr 623).
21. Muller C, Murawski N, Wiesen MH, et al: The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 119:3276-3284, 2012.
22. Salles GA, Morschhauser F, Thieblemont C, et al: Efficacy and safety of obinutuzumab (GA101) monotherapy in relapsed/refractory indolent non- Hodgkin's lymphoma: Results from a phase I/II study (BO20999). Blood 118, 2011 (abstr 268).
23. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998.
24. Foran JM, Cunningham D, Coiffier B, et al: Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response. Ann Oncol 11:117-121, 2000 (suppl 1).
25. Foran JM, Rohatiner AZ, Cunningham D, et al: European phase II study of rituximab (chimeric anti- CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000.
26. Coiffier B, Bosly A, Wu KL, et al: Ofatumumab monotherapy for treatment of patients with relapsed/progressive diffuse large B-cell lymphoma: Results from a multicenter phase II study. Blood 116, 2010 (abstr 3955).
27. Flinn IW, Byrd JC, Furman RR, et al: Evidence of clinical activity in a phase 1 study of CAL-101, an oral P110 isoform-selective inhibitor of phosphatidylinositol 3-kinase, in patients with relapsed or refractory B-cell malignancies. Blood 114, 2009 (abstr 922).
28. Witzig TE, Vose JM, Zinzani PL, et al: An international phase II trial of single-Agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 22:1622- 1627, 2011.
29. Honigberg LA, Smith AM, Sirisawad M, et al: The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 107:13075-13080, 2010.
30. Renner C, Zinzani PL, Gressin R, et al: A multicenter phase II trial (SAKK 36/06) of singleagent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 97:1085-1091, 2012.
31. Coiffier B, Ribrag V, Dupuis J, et al: Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol 29:508s, 2011 (suppl; abstr 8017).
32. Groth-Pedersen L, Ostenfeld MS, Høyer- Hansen M, et al: Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Res 67: 2217-2225, 2007.
33. Morschhauser F, Salles G, Cartron G, et al: Dose selection for phase III studies of the monoclonal anti-CD20 antibody obinutuzumab (GA101): A rational approach. Haematologica 96:390, 2011 (suppl 2; abstr 0935).